Although previous studies have suggested the efficacy of this peptide in inducing transient pulmonary vasodilation in another model of PHT [39], our findings indicate that the chronic continuous intraperitoneal administration of VIP did not provide a decrease in Ppa in the presence of precapillary PHT. This evidence concerns the gene VIP and pulmonary hypertension, primary, 1.